Compare Amphastar Pharmaceuticals Inc (AMPH) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Yum China Holdings Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Yum China Holdings Inc trades at $43.87 (market cap $14.80B). The key difference: Yum China Holdings Inc is far larger — about 17.9× Amphastar Pharmaceuticals Inc's market cap, and Yum China Holdings Inc pays a 2.7% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | YUMC | |
|---|---|---|
Market Cap | $826.08M | $14.80B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $57.95 |
52-Week Low | $16.87 | $40.18 |
Enterprise Value | $1.22B | $15.69B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
YUMC trades at $43.02, up 1.68% today, with a neutral technical signal and strong fundamentals including consistent earnings beats. Revenue grew to $11.80B in 2025, with a net margin of 7.83%. The company recently announced a $0.29 dividend and a $512M share repurchase, while acquiring full ownership of Pizza Hut in mainland China, signaling strategic expansion.
Outlook remains positive with analyst consensus at 74% buy ratings, though risks include China's competitive dining market and currency volatility. The stock's P/E of 16.48 and ROE of 16.87% support value, but investors should monitor Q2 2026 earnings due July 30, 2026, for growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
